#### MIDODRINE HYDROCHLORIDE- midodrine hydrochloride tablet Impax Generics

-----

# MIDODRINE HYDROCHLORIDE TABLETS, 2.5 mg, 5 mg and 10 mg

**Rx only** 

#### WARNING

Because midodrine hydrochloride can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of midodrine hydrochloride in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride, principally improved ability to carry out activities of daily living, have not been verified.

#### DESCRIPTION

Name: Midodrine Hydrochloride Tablets

**Dosage Form:** 2.5 mg, 5 mg and 10 mg tablets for oral administration


Active Ingredient: Midodrine hydrochloride

**Inactive Ingredients :** Microcrystalline Cellulose, NF; Corn Starch, NF; Colloidal Silicon Dioxide, NF; Magnesium Stearate, NF; Talc, USP; FD&C Yellow No. 6 (5 mg tablet); Lake Blend Green (10 mg tablet).

Pharmacological Classification: Vasopressor/Antihypotensive

**Chemical Names** (USAN: Midodrine Hydrochloride): (1) Acetamide, 2-amino-*N*-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]-monohydrochloride,(±)-; (2) (±) -2-amino-*N*-((beta)-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride BAN, INN, JAN: Midodrine

#### Structural Formula:



Molecular Formula: C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> HCl; Molecular Weight: 290.7

Organoleptic Properties: Odorless, white, crystalline powder Solubility: Water: Soluble Methanol: Sparingly soluble pKa: 7.8 (0.3% aqueous solution) pH: 3.5 to 5.5 (5% aqueous solution) Melting Range: 200 to 203°C

# CLINICAL PHARMACOLOGY

#### **Mechanism of Action**

Midodrine hydrochloride forms an active metabolite, desglymidodrine, that is an alpha1-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system. Administration of midodrine HCl results in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with orthostatic hypotension of various etiologies. Standing systolic blood pressure is elevated by approximately 15 to 30 mmHg at 1 hour after a 10 mg dose of midodrine, with some effect persisting for 2 to 3 hours. Midodrine HCl has no clinically significant effect on standing or supine pulse rates in patients with autonomic failure.

#### Pharmacokinetics

Midodrine HCl is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine, formed by deglycination of midodrine. After oral administration, midodrine HCl is rapidly absorbed. The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93%. The bioavailability of desglymidodrine is not affected by food. Approximately the same amount of desglymidodrine is formed after intravenous and oral administration of midodrine. Neither midodrine nor desglymidodrine is bound to plasma proteins to any significant extent.

#### **Metabolism and Excretion**

Thorough metabolic studies have not been conducted, but it appears that deglycination of midodrine to desglymidodrine takes place in many tissues, and both compounds are metabolized in part by the liver. Neither midodrine nor desglymidodrine is a substrate for monoamine oxidase.

Renal elimination of midodrine is insignificant. The renal clearance of desglymidodrine is of the order of 385 mL/minute, most, about 80%, by active renal secretion. The actual mechanism of active secretion has not been studied, but it is possible that it occurs by the base-secreting pathway responsible for the secretion of several other drugs that are bases (see also **Potential for Drug Interactions**).

## **Clinical Studies**

Midodrine has been studied in 3 principal controlled trials, one of 3 weeks duration and 2 of 1 to 2 days duration. All studies were randomized, double-blind and parallel-design trials in patients with orthostatic hypotension of any etiology and supine-to-standing fall of systolic blood pressure of at least 15 mmHg accompanied by at least moderate dizziness/lightheadedness. Patients with pre-existing sustained supine hypertension above 180/110 mmHg were routinely excluded. In a 3-week study in 170 patients, most previously untreated with midodrine, the midodrine-treated patients (10 mg tid, with the

last dose not later than 6 PM) had significantly higher (by about 20 mmHg) 1-minute standing systolic pressure 1 hour after dosing (blood pressures were not measured at other times) for all 3 weeks. After week 1, midodrine-treated patients had small improvements in dizziness/lightheadedness/unsteadiness scores and global evaluations, but these effects were made difficult to interpret by a high early drop-out rate (about 25% vs 5% on placebo). Supine and sitting blood pressure rose 16/8 and 20/10 mmHg, respectively, on average.

In a 2-day study, after open-label midodrine, known midodrine responders received midodrine 10 mg or placebo at 0, 3, and 6 hours. One-minute standing systolic blood pressures were increased 1 hour after each dose by about 15 mmHg and 3 hours after each dose by about 12 mmHg; 3-minute standing pressures were increased also at 1, but not 3, hours after dosing. There were increases in standing time seen intermittently 1 hour after dosing, but not at 3 hours.

In a 1-day, dose-response trial, single doses of 0, 2.5, 10, and 20 mg of midodrine were given to 25 patients. The 10 and 20 mg doses produced increases in standing 1-minute systolic pressure of about 30 mmHg at 1 hour; the increase was sustained in part for 2 hours after 10 mg and 4 hours after 20 mg. Supine systolic pressure was  $\geq$ 200 mmHg in 22% of patients on 10 mg and 45% of patients on 20 mg; elevated pressures often lasted 6 hours or more.

## **Special Populations**

A study with 16 patients undergoing hemodialysis demonstrated that midodrine hydrochloride is removed by dialysis.

# INDICATIONS AND USAGE

Midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine HCl can cause marked elevation of supine blood pressure (BP >200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine HCl's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine HCl, principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine HCl.

After initiation of treatment, midodrine HCl tablets should be continued only for patients who report significant symptomatic improvement.

# CONTRAINDICATIONS

Midodrine hydrochloride tablets are contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma or thyrotoxicosis. Midodrine HCl tablets should not be used in patients with persistent and excessive supine hypertension.

## WARNINGS

## Supine Hypertension

The most potentially serious adverse reaction associated with midodrine hydrochloride therapy is marked elevation of supine arterial blood pressure (supine hypertension). Systolic pressure of about 200 mmHg were seen overall in about 13.4% of patients given 10 mg of midodrine HCl. Systolic elevations of this degree were most likely to be observed in patients with relatively elevated pre-treatment systolic blood pressures (mean 170 mmHg). There is no experience in patients with initial supine systolic pressure above 180 mmHg, as those patients were excluded from the clinical trials. Use of midodrine HCl tablets in such patients is not recommended. Sitting blood pressures were also elevated by midodrine HCl therapy. It is essential to monitor supine and sitting blood pressures in patients maintained on midodrine HCl. Uncontrolled hypertension increases the risk of cardiovascular events, particularly stroke.

# PRECAUTIONS

# General

The potential for supine and sitting hypertension should be evaluated at the beginning of midodrine hydrochloride therapy. Supine hypertension can often be controlled by preventing the patient from becoming fully supine, i.e., sleeping with the head of the bed elevated. The patient should be cautioned to report symptoms of supine hypertension immediately. Symptoms may include cardiac awareness, pounding in the ears, headache, blurred vision, etc. The patient should be advised to discontinue the medication immediately if supine hypertension persists. Blood pressure should be monitored carefully when midodrine HCl is used concomitantly with other agents that cause vasoconstriction, such as phenylephrine, ephedrine, dihydroergotamine, phenylpropanolamine, or pseudoephedrine.

A slight slowing of the heart rate may occur after administration of midodrine HCl, primarily due to vagal reflex. Caution should be exercised when midodrine HCl is used concomitantly with cardiac glycosides (such as digitalis), psychopharmacologic agents, beta blockers or other agents that directly or indirectly reduce heart rate. Patients who experience any signs or symptoms suggesting bradycardia (pulse slowing, increased dizziness, syncope, cardiac awareness) should be advised to discontinue midodrine HCl and should be re-evaluated.

Midodrine HCl should be used cautiously in patients with urinary retention problems, as desglymidodrine acts on the alpha-adrenergic receptors of the bladder neck.

Midodrine HCl should be used with caution in orthostatic hypotensive patients who are also diabetic, as well as those with a history of visual problems who are also taking fludrocortisone acetate, which is known to cause an increase in intraocular pressure and glaucoma.

Midodrine HCl use has not been studied in patients with renal impairment. Because desglymidodrine is eliminated via the kidneys, and higher blood levels would be expected in such patients. Midodrine HCl should be used with caution in patients with renal impairment, with a starting dose of 2.5 mg (see **DOSAGE AND ADMINISTRATION**). Renal function should be assessed prior to initial use of midodrine HCl.

Midodrine HCl use has not been studied in patients with hepatic impairment. Midodrine HCl should be used with caution in patients with hepatic impairment, as the liver has a role in the metabolism of midodrine.

## **Information for Patients**

Patients should be told that certain agents in over-the-counter products, such as cold remedies and diet aids, can elevate blood pressure, and therefore, should be used cautiously with midodrine HCl, as they may enhance or potentiate the pressor effects of midodrine HCl (see **Drug Interactions**). Patients should also be made aware of the possibility of supine hypertension. They should be told to avoid taking their dose if they are to be supine for any length of time, i.e., they should take their last daily dose of midodrine HCl tablets 3 to 4 hours before bedtime to minimize nighttime supine hypertension.

# Laboratory Tests

Since desglymidodrine is eliminated by the kidneys and the liver has a role in its metabolism, evaluation of the patient should include assessment of renal and hepatic function prior to initiating therapy and subsequently, as appropriate.

# **Drug Interactions**

When administered concomitantly with midodrine HCl, cardiac glycosides may enhance or precipitate bradycardia, A.V. block or arrhythmia.

The risk of hypertension increases with concomitant administration of drugs that increase blood pressure (phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, or droxidopa). Avoid concomitant use of drugs that increase blood pressure. If concomitant use cannot be avoided, monitor blood pressure closely.

Avoid use of MAO inhibitors or linezolid with midodrine.

Midodrine HCl has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. The potential for supine hypertension should be carefully monitored in these patients and may be minimized by either reducing the dose of fludrocortisone acetate or decreasing the salt intake prior to initiation of treatment with midodrine HCl. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of midodrine HCl.

## **Potential for Drug Interactions**

It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. Thus there may be a potential for drug-drug interactions with these drugs.

## Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies have been conducted in rats and mice at dosages of 3 to 4 times the maximum recommended daily human dose on a mg/m<sup>2</sup> basis, with no indication of carcinogenic effects related to midodrine HCl. Studies investigating the mutagenic potential of midodrine HCl revealed no evidence of mutagenicity. Other than the dominant lethal assay in male mice, where no impairment of fertility was observed, there have been no studies on the effects of midodrine HCl on fertility.

# Pregnancy

# Pregnancy Category C

Midodrine HCl increased the rate of embryo resorption, reduced fetal body weight in rats and rabbits, and decreased fetal survival in rabbits when given in doses 13 (rat) and 7 (rabbit) times the maximum human dose based on body surface area (mg/m<sup>2</sup>). There are no adequate and well-controlled studies in pregnant women. Midodrine HCl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No teratogenic effects have been observed in studies in rats and rabbits.

## **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when midodrine HCl tablets are administered to a nursing woman.

# Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

# **ADVERSE REACTIONS**

The most frequent adverse reactions seen in controlled trials were supine and sitting hypertension; paresthesia and pruritus, mainly of the scalp; goosebumps; chills; urinary urge; urinary retention and urinary frequency.

The frequency of these events in a 3-week placebo-controlled trial is shown in the following table:

	Placebo n=88			odrine =82
Event	# of reports	% of patients	# of reports	% of patients
Total # of reports	22		77	
Paresthesia <sup>*</sup>	4	4.5	15	18.3
Piloerection	0	0	11	13.4
Dysuria <sup>†</sup>	0	0	11	13.4
Pruritus <sup>‡</sup>	2	2.3	10	12.2
Supine hypertension <sup>§</sup>	0	0	6	7.3
Chills	0	0	4	4.9
Pain¶	0	0	4	4.9
Rash	1	1.1	2	2.4

# **Adverse Events**

\* Includes hyperesthesia and scalp paresthesia

<sup>†</sup> Includes dysuria (1), increased urinary frequency (2), impaired urination (1), urinary retention (5), urinary urgency (2)

<sup>‡</sup> Includes scalp pruritus

\$ Includes patients who experienced an increase in supine hypertension

 $\P$  Includes abdominal pain and pain increase

Less frequent adverse reactions were headache; feeling of pressure/fullness in the head; vasodilation/flushing face; confusion/thinking abnormality; dry mouth; nervousness/anxiety and rash. Other adverse reactions that occurred rarely were visual field defect; dizziness; skin hyperesthesia; insomnia; somnolence; erythema multiforme; canker sore; dry skin; dysuria; impaired urination; asthenia; backache; pyrosis; nausea; gastrointestinal distress; flatulence and leg cramps.

The most potentially serious adverse reaction associated with midodrine hydrochloride therapy is supine hypertension. The feelings of paresthesia, pruritus, piloerection and chills are pilomotor reactions associated with the action of midodrine on the alpha-adrenergic receptors of the hair follicles. Feelings of urinary urgency, retention and frequency are associated with the action of midodrine on the alpha-receptors of the bladder neck.

# OVERDOSAGE

Symptoms of overdose could include hypertension, piloerection (goosebumps), a sensation of coldness and urinary retention. There are 2 reported cases of overdosage with midodrine hydrochloride tablets, both in young males. One patient ingested midodrine HCl drops, 250 mg, experienced systolic blood pressure of greater than 200 mmHg, was treated with an IV injection of 20 mg of phentolamine, and was discharged the same night without any complaints. The other patient ingested 205 mg of midodrine HCl (41 5-mg tablets), and was found lethargic and unable to talk, unresponsive to voice but responsive to painful stimuli, hypertensive and bradycardic. Gastric lavage was performed, and the patient recovered fully by the next day without sequelae.

The single doses that would be associated with symptoms of overdosage or would be potentially life-threatening are unknown. The oral  $LD_{50}$  is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs.

Desglymidodrine is dialyzable.

Recommended general treatment, based on the pharmacology of the drug, includes induced emesis and

administration of alpha-sympatholytic drugs (e.g., phentolamine).

# DOSAGE AND ADMINISTRATION

The recommended dose of midodrine hydrochloride tablets is 10 mg, 3 times daily. Dosing should take place during the daytime hours when the patient needs to be upright, pursuing the activities of daily living. A suggested dosing schedule of approximately 4-hour intervals is as follows: shortly before or upon arising in the morning, midday, and late afternoon (not later than 6 PM). Doses may be given in 3-hour intervals, if required, to control symptoms, but not more frequently. Single doses as high as 20 mg have been given to patients, but severe and persistent systolic supine hypertension occurs at a high rate (about 45%) at this dose. In order to reduce the potential for supine hypertension during sleep, midodrine HCl tablets should not be given after the evening meal or less than 4 hours before bedtime. Total daily doses greater than 30 mg have been tolerated by some patients, but their safety and usefulness have not been studied systematically or established. Because of the risk of supine hypertension, midodrine HCl tablets should be continued only in patients who appear to attain symptomatic improvement during initial treatment.

The supine and standing blood pressure should be monitored regularly, and the administration of midodrine HCl tablets should be stopped if supine blood pressure increases excessively.

Because desglymidodrine is excreted renally, dosing in patients with abnormal renal function should be cautious; although this has not been systematically studied, it is recommended that treatment of these patients be initiated using 2.5 mg doses.

Dosing in children has not been adequately studied.

Blood levels of midodrine and desglymidodrine were similar when comparing levels in patients 65 or older vs. younger than 65 and when comparing males vs. females, suggesting dose modifications for these groups are not necessary.

# HOW SUPPLIED

Midodrine hydrochloride is supplied as 2.5 mg, 5 mg and 10 mg tablets for oral administration. Each 2.5 mg tablet is white, round, with "G" bisect "421" engraved on one side and plain on the other side. Each 5 mg tablet is light orange, round, with "G" bisect "422" engraved on one side and plain on the other side. Each 10 mg tablets is light green, round, with "G" bisect "423" engraved on one side and plain on the other side. Each 10 mg tablets is light green, round, with "G" bisect "423" engraved on one side and plain on the other side.

2.5 mg Tablets:	
Bottle of 100	NDC 0115-4211-01
Bottle of 500	NDC 0115-4211-02
Bottle of 1000	NDC 0115-4211-03

5 mg Tablets:	
Bottle of 100	NDC 0115-4222-01
Bottle of 500	NDC 0115-4222-02
Bottle of 1000	NDC 0115-4222-03

10 mg Tablets:	
Bottle of 100	NDC 0115-4233-01
Bottle of 500	NDC 0115-4233-02
Bottle of 1000	NDC 0115-4233-03

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

Dispense in a tightly-closed, light-resistant container as defined in the USP, with a child-resistant closure, as required.

Dist. by: Impax Generics Hayward, CA 94544

506-05 Rev. 02/2017

## PRINCIPAL DISPLAY PANEL - 2.5 mg Tablet Bottle Label

## **Impax Generics**

NDC 0115-4211-01

Midodrine HCl Tablets

2.5 mg\*

Rx only 100 Tablets



## PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label

## **Impax Generics**

NDC 0115-4222-01

## Midodrine HCl Tablets

## 5 mg\*

Rx only 100 Tablets



#### **PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label**


#### **Impax Generics**

NDC 0115-4233-01

Midodrine HCl Tablets

10 mg\*

Rx only 100 Tablets



MIDODRINE HYDROCH midodrine hydrochloride tablet	ILORIDE				
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Ite m C	ode (Source)	NDC:01	15-4211
Route of Administration	ORAL				
Active Ingredient/Active Moi	ety				
Ingi	redient Name		Basis of Stren	gth	Strength
MIDO DRINE HYDRO CHLO RIDE (UNI UNII:6 YE7PBM15H)	II: 59JV96YTXV) (MIDODRINE -		MIDO DRINE HYDRO CHLO RIDE		2.5 mg
Inactive Ingredients					

			Ing	redient Nam	e		Strength
CE	LLULOSE, MICRO	OCRYSTA	LLINE (UNII: OP	1R32D61U)			
sт	ARCH, CORN (UN	II: O8232N	Y3SJ)				
SI	LICON DIO XIDE (U	JNII: ETJ72	Z6XBU4)				
M	GNESIUM STEAR	ATE (UNI	l:70097M6I30)				
TA	LC (UNII: 7SEV7J4	R1U)					
<b>D</b> -	oduct Charact	<b>!</b> - <b>4!</b>					
		eristics		0			Duringen
	lor		WHITE	Scor			2 pieces
	ape		ROUND	Size			7mm
Flá	vor			Impi	rint Code		G;421
C				F			
Co	ntains						
Co							
	ntains						
Pa	ntains		Decker			Malacia Start Data	Malatine Falls
Pa #	ntains Ickaging Item Code		U	Description		Marketing Start Date	Marketing End Dat
<b>P</b> a #	ntains nckaging Item Code NDC:0115-4211-01		BOTTLE; Type 0:	<b>Description</b> Not a Combinat	tion Product	05/27/2004	Marketing End Date
Pa # 1	ntains ackaging Item Code NDC:0115-4211-01 NDC:0115-4211-02	500 in 1 H	BOTTLE; Type 0: BOTTLE; Type 0:	<b>Description</b> Not a Combinat Not a Combina	tion Product tion Product	05/27/2004 05/27/2004	Marketing End Date
Pa # 1	ntains nckaging Item Code NDC:0115-4211-01	500 in 1 H	BOTTLE; Type 0: BOTTLE; Type 0:	<b>Description</b> Not a Combinat Not a Combina	tion Product tion Product	05/27/2004	Marketing End Date
Pa # 1	ntains ackaging Item Code NDC:0115-4211-01 NDC:0115-4211-02	500 in 1 H	BOTTLE; Type 0: BOTTLE; Type 0:	<b>Description</b> Not a Combinat Not a Combina	tion Product tion Product	05/27/2004 05/27/2004	Marketing End Dat
Pa # 1	ntains ackaging Item Code NDC:0115-4211-01 NDC:0115-4211-02	500 in 1 H	BOTTLE; Type 0: BOTTLE; Type 0:	<b>Description</b> Not a Combinat Not a Combina	tion Product tion Product	05/27/2004 05/27/2004	Marketing End Dat
Pa # 1 3	ntains ackaging Item Code NDC:0115-4211-01 NDC:0115-4211-02	500 in 1 E 1000 in 1	3OTTLE; Type 0: 3OTTLE; Type 0: BOTTLE; Type 0	<b>Description</b> Not a Combinat Not a Combina	tion Product tion Product	05/27/2004 05/27/2004	Marketing End Dat
Pa # 1 3	ntains nckaging Item Code NDC:0115-4211-01 NDC:0115-4211-02 NDC:0115-4211-03	500 in 1 E 1000 in 1	3OTTLE; Type 0: 3OTTLE; Type 0: BOTTLE; Type 0	<b>Description</b> Not a Combinat Not a Combina : Not a Combin	tion Product tion Product ation Product	05/27/2004 05/27/2004	
Pa # 1 2 3 3 M	ntains nckaging Item Code NDC:0115-4211-01 NDC:0115-4211-02 NDC:0115-4211-03	500 in 1 F 1000 in 1 format cy App	BOTTLE; Type 0: BOTTLE; Type 0: BOTTLE; Type 0	<b>Description</b> Not a Combinat Not a Combina : Not a Combin	tion Product tion Product ation Product	05/27/2004 05/27/2004 05/27/2004	Marketing End Date

midodrine hydrochloride table					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Ite m C	ode (Source)	NDC:01	15-4222
Route of Administration	ORAL				
Active Ingredient/Active	Moiety				
	Ingredient Name		Basis of Stre	ngth	Strengt
MIDO DRINE HYDRO CHLO RID UNII:6 YE7PBM15H)	E (UNII: 59JV96YTXV) (MIDODRINE -		MIDO DRINE HYDRO CHLO RIDE		5 mg
Inactive Ingredients					
	Ingredient Name			Str	rength
CELLULOSE, MICROCRYSTAI	LLINE (UNII: OP1R32D61U)				
STARCH, CORN (UNII: 08232N)	/3SJ)				
SILICON DIOXIDE (UNII: ETJ7Z	6XBU4)				

MAGNESIUM STEARATE (UNII: 70097M6I30)

TALC (UNII: 7SEV7J4	R1U)					
FD&C YELLOW NO.	6 (UNII: H77VEI	93A8)				
Product Charact	eristics					
Color	ORANGE (ligh	torange)	Score		2 piec	es
Shape	ROUND		Size		7mm	
Flavor			Imprint Co	ode	G;422	
Contains						
Packaging						
# Item Code		Package Description	Market	ing Start Date	Marketin	g End Date
<b>1</b> NDC:0115-4222-01	100 in 1 BOTTL	E; Type 0: Not a Combination Product	05/27/20	04		
<b>2</b> NDC:0115-4222-02	500 in 1 BOTTL	E; Type 0: Not a Combination Product	05/27/20	04		
<b>3</b> NDC:0115-4222-03	1000 in 1 BOTT	LE; Type 0: Not a Combination Product	05/27/20	04		
Marketing Inf	formation					
0			Maulta		Maultatin	a End Data
Marketing Categor		on Number or Monograph Citation		ting Start Date	Markeun	g End Date
ANDA	ANDA07644	J	05/27/20	04		
		ILORIDE				
nidodrine hydrochle	oride tablet	ILORIDE				
nidodrine hydrochk <b>Product Informa</b>	oride tablet	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:0	115-4233
nidodrine hydrochk <b>Product Informa</b> Product Type	oride tablet	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:0	115-4233
nidodrine hydrochk <b>Product Informa</b> Product Type	oride tablet		Item Co	ode (Source)	NDC:0	115-4233
nidodrine hydrochk <b>Product Informa</b> Product Type	oride tablet	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:0	115-4233
nidodrine hydrochk <b>Product Informa</b> Product Type Route of Administra	oride tablet ntion ation	HUMAN PRESCRIPTION DRUG ORAL	Item Co	ode (Source)	NDC:0	115-4233
nidodrine hydrochk <b>Product Informa</b> Product Type Route of Administra	oride tablet ntion ation nt/Active Moi	HUMAN PRESCRIPTION DRUG ORAL	Item Co	ode (Source) Basis of St		115-4233 Strengtl
Active Ingredien	oride tablet ntion ation nt/Active Moi Ing	HUMAN PRESCRIPTION DRUG ORAL	Item Co		rength	
midodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO	oride tablet ntion ation nt/Active Moi Ing	HUMAN PRESCRIPTION DRUG ORAL ety redient Name	Item Co	<b>Basis of St</b> MIDODRINE	rength	Strengt
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO UNII:6 YE7PBM15H)	oride tablet ntion ation nt/Active Moi Ing: CHLORIDE (UN	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59JV96 YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredie	oride tablet ntion ation nt/Active Moi Ing: CHLORIDE (UN	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59JV96YTXV) (MIDODRINE - III: 59JV96YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDO DRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredie CELLULOSE, MICRO	oride tablet ntion ation ht/Active Moi Ing: CHLORIDE (UN ents	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59JV96YTXV) (MIDODRINE - III: 59JV96YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredie CELLULOSE, MICRO STARCH, CORN (UNI	oride tablet ation ation ht/Active Moi Ing: CHLORIDE (UN ents DCRYSTALLINE E: 08232NY3SJ)	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59 JV96 YTXV) (MIDODRINE - III: 59 JV96 YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDO DRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredie CELLULOSE, MICRO STARCH, CORN (UNI SILICON DIO XIDE (U	oride tablet ation ation ht/Active Moi Ing: CHLORIDE (UN ents OCRYSTALLINE E: 08232NY3SJ) JNII: ETJ7Z6 XBU	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59JV96 YTXV) (MIDODRINE - II: 59JV96 YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredie CELLULOSE, MICRO STARCH, CORN (UNI SILICON DIOXIDE (UMAGNESIUM STEAR	oride tablet ation ation ht/Active Moi Ing: CHLORIDE (UN ents DCRYSTALLINE E: 08232NY3SJ) JNII: ETJ7Z6 XBU ATE (UNII: 7009	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59JV96 YTXV) (MIDODRINE - II: 59JV96 YTXV) (MIDODRINE -	Item Co	<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDO DRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredia STARCH, CORN (UNI SILICON DIO XIDE (UNI MAGNESIUM STEAR TALC (UNII: 7SEV7J4	oride tablet ation ation ht/Active Moi Ing: CHLORIDE (UN Ents OCRYSTALLINE I: 08232NY3SJ) JNII: ETJ7Z6 XBU ATE (UNII: 7009 R1U)	HUMAN PRESCRIPTION DRUG ORAL oRAL ety redient Name II: 59 JV96 YTXV) (MIDODRINE - II: 59 JV96 YTXV) (MIDODRINE - II: 0P1R32D6 1U) II: 0P1R32D6 1U)		<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO UNII:6 YE7PBM15H) Inactive Ingredia CELLULOSE, MICRO STARCH, CORN (UNI SILICON DIO XIDE (UNI SILICON DIO XIDE (UNI MAGNESIUM STEAR TALC (UNII: 7SEV7J4 D&C YELLOW NO. 1	oride tablet ation at	HUMAN PRESCRIPTION DRUG ORAL ety redient Name II: 59 JV96 YTXV) (MIDODRINE - III OP1R32D6 1U) III OP1R32D6 1U) IIII OP1R32D6 1U)		<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg
nidodrine hydrochk Product Informa Product Type Route of Administra Active Ingredien MIDODRINE HYDRO	oride tablet ation ation ation t/Active Moi Ing: CHLORIDE (UN ents CHLORIDE (UN Ents DCRYSTALLINE I: 08232NY3SJ) JNII: ETJ7Z6XBU ATE (UNII: 7009 R1U) 0 (UNII: 35SW5U JNII: H3R47K3TB	HUMAN PRESCRIPTION DRUG ORAL ORAL ts 59 JV96 YTXV) (MIDODRINE - LI: 59 JV96 YTXV) (MIDODRINE - (UNII: OP1R32D6 1U) CUNII: OP1R32D6 1U) CUNII: OP1R32D6 1U) CUNII: OP1R32D6 1U)		<b>Basis of St</b> MIDODRINE	r <b>ength</b> E	Strengt 10 mg

<b>Product Charact</b>	eristics			
Color	GREEN (light green)	core	2 pieces	
Shape	ROUND S	ize	7mm	
Flavor	b	nprint Code	G;423	
Contains				
Packaging				
			MI C. DID.	
# Item Code	Package Description	Marketing Start Date	Marketing End Date	
	Package Description           100 in 1 BOTTLE; Type 0: Not a Combination Product		Marketing End Date	
1 NDC:0115-4233-01		12/16/2005	Marketing End Date	
<ol> <li>NDC:0115-4233-01</li> <li>NDC:0115-4233-02</li> </ol>	100 in 1 BOTTLE; Type 0: Not a Combination Product	12/16/2005 12/16/2005	Marketing End Date	
1         NDC:0115-4233-01           2         NDC:0115-4233-02	100 in 1 BOTTLE; Type 0: Not a Combination Product 500 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Produc	12/16/2005 12/16/2005	Marketing End Dat	
<ol> <li>NDC:0115-4233-01</li> <li>NDC:0115-4233-02</li> <li>NDC:0115-4233-03</li> </ol>	100 in 1 BOTTLE; Type 0: Not a Combination Product 500 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Produc <b>Formation</b>	12/16/2005 12/16/2005 t 12/16/2005	Marketing End Date	

Labeler - Impax Generics (079832487)

Revised: 2/2017

Impax Generics